Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies

Infection and Immunity

Volumn 72, Issue 6, 2004, Pages 3622-3627

  Späth, Gerald F ^a,c   Lye, Lon Fye ^a   Segawa, Hiroaki ^b   Turco, Salvatore J ^b   Beverley, Stephen M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN DERIVATIVE; GLYCOCONJUGATE; GUANOSINE DIPHOSPHATE MANNOSE; LIPOPHOSPHOGLYCAN; LIPOPHOSPHOGLYCAN 2; PHOSPHOGLYCAN; PROTOZOAL VACCINE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DEVELOPMENTAL STAGE; FEMALE; GOLGI COMPLEX; IMMUNIZATION; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; MACROPHAGE; MAMMAL; MOUSE; NONHUMAN; PARASITE VIRULENCE; PERSISTENT INFECTION; PRIORITY JOURNAL; PROMASTIGOTE; REVERTANT; SYNTHESIS;

ANIMALS; FEMALE; GLYCOCONJUGATES; GLYCOSPHINGOLIPIDS; HUMANS; IMMUNIZATION; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MACROPHAGES, PERITONEAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MUTATION; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; VIRULENCE;

EID: 2542594797     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.72.6.3622-3627.2004     Document Type: Article

References (33)

1. Belkaid, Y., B. Butcher, and D. L. Sacks. 1998. Analysis of cytokine production by inflammatory mouse macrophages at the single-cell level: selective impairment of IL-12 induction in Leishmania-infected cells. Eur. J. Immunol. 28:1389-1400.
2. + regulatory T cells control Leishmania major persistence and immunity. Nature 420:502-507.
3. Bogdan, C., N. Donhauser, R. Doring, M. Rollinghoff, A. Diefenbach, and M. G. Rittig. 2000. Fibroblasts as host cells in latent leishmaniosis. J. Exp Med. 191:2121-2130.
4. Colmenares, M., S. Kar, K. Goldsmith-Pestana, and D. McMahon-Pratt. 2002. Mechanisms of pathogenesis: differences amongst Leishmania species. Trans. R. Soc. Trop. Med. Hyg. 96(Suppl. 1):S3-S7.
5. Cruz, A. K., R. Titus, and S. M. Beverley. 1993. Plasticity in chromosome number and testing of essential genes in Leishmania by targeting. Proc. Natl. Acad. Sci. USA 90:1599-1603.
6. de Ibarra, A. A., J. G. Howard, and D. Snary. 1982. Monoclonal antibodies to Leishmania tropica major: specificities and antigen location. Parasitology 85:523-531.
7. Garami, A., A. Mehlert, and T. Ilg. 2001. Glycosylation defects and virulence phenotypes of Leishmania mexicana phosphomannomutase and dolicholphosphate-mannose synthase gene deletion mutants. Mol. Cell. Biol. 21:8168-8183.
8. Handman, E., and D. V. Bullen. 2002. Interaction of Leishmania with the host macrophage. Trends Parasitol. 18:332-334.
9. Holaday, B. J., M. M. Pompeu, S. Jeronimo, M. J. Texeira, A. Sousa Ade, A. W. Vasconcelos, R. D. Pearson, J. S. Abrams, and R. M. Locksley. 1993. Potential role for interleukin-10 in the immunosuppression associated with kala azar. J. Clin. Investig. 92:2626-2632.
10. Ilg, T., M. Demar, and D. Harbecke. 2001. Phosphoglycan repeat-deficient Leishmania mexicana parasites remain infectious to macrophages and mice. J. Biol. Chem. 276:4988-4997.
11. Ilg, T., E. Handman, and Y. D. Stierhof. 1999. Proteophosphoglycans from Leishmania promastigotes and amastigotes. Biochem. Soc. Trans. 27:518-525.
12. Joshi, P. B., B. L. Kelly, S. Kamhawi, D. L. Sacks, and W. R. McMaster. 2002. Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor. Mol. Biochem. Parasitol. 120:33-40.
13. Kapler, G. M., C. M. Coburn, and S. M. Beverley. 1990. Stable transfection of the human parasite Leishmania major delineates a 30-kilobase region sufficient for extrachromosomal replication and expression. Mol. Cell. Biol. 10:1084-1094.
14. McConville, M. J., T. A. Collidge, M. A. Ferguson, and P. Schneider. 1993. The glycoinositol phospholipids of Leishmania mexicana promastigotes. Evidence for the presence of three distinct pathways of glycolipid biosynthesis. J. Biol. Chem. 268:15595-15604.
15. Modabber, F. 1995. Vaccines against leishmaniasis. Ann. Trop. Med. Parasitol. 89(Suppl. 1):83-88.
16. Racoosin, E. L., and S. M. Beverley. 1997. Leishmania major: promastigotes induce expression of a subset of chemokine genes in murine macrophages. Exp. Parasitol. 85:283-295.
17. Ralton, J. E., T. Naderer, H. L. Piraino, T. A. Bashtannyk, J. M. Callaghan, and M. J. McConville. 2003. Evidence that intracellular beta1-2 mannan is a virulence factor in Leishmania parasites. J. Biol. Chem. 278:40757-40763.
18. Sacks, D., and N. Noben-Trauth. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2:845-858.
19. Satti, I. N., H. Y. Osman, N. S. Daifalla, S. A. Younis, E. A. Khalil, E. E. Zijlstra, A. M. El Hassan, and H. W. Ghalib. 2001. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers. Vaccine 19:2100-2106.
20. Scott, P. 2003. Development and regulation of cell-mediated immunity in experimental leishmaniasis. Immunol. Res. 27:489-498.
21. Späth, G. F., and S. M. Beverley. 2001. A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp. Parasitol. 99:97-103.
22. Späth, G. F., L. Epstein, B. Leader, S. M. Singer, H. A. Avila, S. J. Turco, and S. M. Beverley. 2000. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. Proc. Natl. Acad. Sci. USA 97:9258-9263.
23. Späth, G. F., L. A. Garraway, S. J. Turco, and S. M. Beverley. 2003. The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc. Natl. Acad. Sci. USA 100:9536-9541.
24. Späth, G. F., L. F. Lye, H. Segawa, D. L. Sacks, S. J. Turco, and S. M. Beverley. 2003. Persistence without pathology in phosphoglycan-deficient Leishmania major. Science 301:1241-1243.
25. Stenger, S., N. Donhauser, H. Thuring, M. Rollinghoff, and C. Bogdan. 1996. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J. Exp. Med. 183:1501-1514.
26. Titus, R. G., M. Marchand, T. Boon, and J. A. Louis. 1985. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 7:545-555.
27. Tolson, D. L., S. J. Turco, R. P. Beecroft, and T. W. Pearson. 1989. The immunochemical structure and surface arrangement of Leishmania donovani lipophosphoglycan determined using monoclonal antibodies. Mol. Biochem. Parasitol. 35:109-118.
28. Turco, S. J., and A. Descoteaux. 1992. The lipophosphoglycan of Leishmania parasites. Annu. Rev. Microbiol. 46:65-94.
29. Turco, S. J., G. F. Späth, and S. M. Beverley. 2001. Is lipophosphoglycan a virulence factor? A surprising diversity between Leishmania species. Trends Parasitol. 17:223-226.
30. Uzonna, J., G. Späth, S. M. Beverley, and P. Scott. 2004. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol. 172:3793-3797.
31. Uzonna, J. E., G. Wei, D. Yurkowski, and P. Bretscher. 2001. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J. Immunol. 167:6967-6974.
32. Zhang, K., M. Showalter, J. Revollo, F. F. Hsu, J. Turk, and S. M. Beverley. 2003. Sphingolipids are essential for differentiation but not growth in Leishmania. EMBO J. 22:6016-6026.
33. Zufferey, R., S. Allen, T. Barron, D. R. Sullivan, P. W. Denny, I. C. Almeida, D. F. Smith, S. J. Turco, M. A. Ferguson, and S. M. Beverley. 2003. Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major. J. Biol. Chem. 278:44708-44718.